organization · Reporting owner
Leadiant Biosciences, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLIGENIX, INC.
Report date November 29, 2017 · Filed December 01, 2017
Jointly reported with Essetifin SPA, CAVAZZA PAOLO, Cavazza Enrico, Cavazza Francesca, Cavazza Silvia, Cavazza Preta Martina
Section 16 reporting ended · disclosed 2017-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectIndirect | 0 |
Reported balance
After 2017-11-29 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-11-29 · Sale · Disposed 271,140 · Balance 0 F1: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F2: This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer. F3: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F6: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectIndirect | 0 |
Reported balance
After 2017-11-29 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2017-11-29 · Sale · Disposed 5,954 · Balance 0 F1: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F4: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F6: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectIndirect | 0 |
Reported balance
After 2017-11-29 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2017-11-29 · Sale · Disposed 16,416 · Balance 0 F1: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F5: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F6: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 271,140 |
Reported balance
After 2017-11-29 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-11-29 · Purchase · Acquired 271,140 · Balance 271,140 F1: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F2: This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer. F3: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F6: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 277,094 |
Reported balance
After 2017-11-29 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2017-11-29 · Purchase · Acquired 5,954 · Balance 277,094 F1: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F4: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F6: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 293,510 |
Reported balance
After 2017-11-29 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2017-11-29 · Purchase · Acquired 16,416 · Balance 293,510 F1: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F5: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F6: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split.
F2: This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer.
F3: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock.
F4: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin.
F5: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin.
F6: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | PurchaseCommon Stock | 16,416 | $2.12 | $34,801.92 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 6 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,510 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F5 · balance_after: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F5 · ownership.direct: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | SaleCommon Stock | 16,416 | $2.12 | $34,801.92 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 5 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F5 · balance_after: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F5 · ownership.direct: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. F5 · ownership.nature: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | PurchaseCommon Stock | 5,954 | $2.12 | $12,622.48 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 4 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,094 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F4 · balance_after: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F4 · ownership.direct: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | SaleCommon Stock | 5,954 | $2.12 | $12,622.48 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 3 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F4 · balance_after: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F4 · ownership.direct: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. F4 · ownership.nature: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | PurchaseCommon Stock | 271,140 | $2.12 | $574,816.80 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 2 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,140 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer. F3 · balance_after: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F3 · ownership.direct: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | SaleCommon Stock | 271,140 | $2.12 | $574,816.80 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 1 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer. F3 · balance_after: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F3 · ownership.direct: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. F3 · ownership.nature: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.